Literature DB >> 30653927

Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.

Ayodeji Adegunsoye1, Justin M Oldham2, Shashi K Bellam3, Steven Montner4, Matthew M Churpek1,5, Imre Noth6, Rekha Vij1, Mary E Strek1, Jonathan H Chung4.   

Abstract

Rationale: Honeycombing on chest computed tomography (CT) has been described in diverse forms of interstitial lung disease (ILD); however, its prevalence and association with mortality across the spectrum of ILD remains unclear. Objective: To determine the prevalence and prognostic value of CT honeycombing and characterize associated mortality patterns across diverse ILD subtypes in a multicenter cohort.
Methods: This was an observational cohort study of adult participants with multidisciplinary or adjudicated ILD diagnosis and documentation of chest CT imaging at index diagnosis across five U.S. hospitals (one tertiary and four nontertiary medical centers). Participants were stratified based on presence or absence of CT honeycombing. Vital status was determined from review of medical records and social security death index. Transplant-free survival was analyzed using univariate and multivariable Cox regression.
Results: The sample comprised 1,330 participants (mean age, 66.8 yr; 50% men) with 4,831 person-years of follow-up. The prevalences of CT honeycombing were 42.0%, 41.9%, 37.6%, and 28.6% in chronic hypersensitivity pneumonitis, connective tissue disease-related ILD (CTD-ILD), idiopathic pulmonary fibrosis (IPF), and unclassifiable/other ILDs, respectively. Among those with CT honeycombing, cumulative mortality hazards were similar across ILD subtypes, except for CTD-ILD, which had a lower mortality hazard. Overall, the mean survival time was shorter among those with CT honeycombing (107 mo; 95% confidence interval [CI], 92-122 mo) than those without CT honeycombing (161 mo; 95% CI, 147-174 mo). CT honeycombing was associated with an increased mortality rate (hazard ratio, 1.72; 95% CI, 1.38-2.14) even after adjustment for center, sex, age, forced vital capacity, diffusing capacity, ILD subtype, and use of immunosuppressive therapy (hazard ratio, 1.62; 95% CI, 1.29-2.02). CT honeycombing was associated with an increased mortality rate within non-IPF ILD subgroups (chronic hypersensitivity pneumonitis, CTD-ILD, and unclassifiable/other ILD). In IPF, however, mortality rates were similar between those with and without CT honeycombing. Conclusions: CT honeycombing is prevalent in diverse forms of ILD and uniquely identifies a progressive fibrotic ILD phenotype with a high mortality rate similar to IPF. CT honeycombing did not confer additional risk in IPF, which is already known to be a progressive fibrotic ILD phenotype regardless of the presence of CT honeycombing.

Entities:  

Keywords:  CT; honeycombing; interstitial lung disease; mortality; pulmonary fibrosis

Mesh:

Year:  2019        PMID: 30653927      PMCID: PMC6491052          DOI: 10.1513/AnnalsATS.201807-443OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  38 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis.

Authors:  Takeshi Johkoh; Fumikazu Sakai; Satoshi Noma; Masanori Akira; Kiminori Fujimoto; Takeyuki Watadani; Yukihiko Sugiyama
Journal:  Eur J Radiol       Date:  2013-06-24       Impact factor: 3.528

3.  Prognosticating Outcomes in Interstitial Lung Disease by Mediastinal Lymph Node Assessment. An Observational Cohort Study with Independent Validation.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Catherine Bonham; Cara Hrusch; Paul Nolan; Wesley Klejch; Shashi Bellam; Uday Mehta; Kiran Thakrar; Janelle Vu Pugashetti; Aliya N Husain; Steven M Montner; Christopher M Straus; Rekha Vij; Anne I Sperling; Imre Noth; Mary E Strek; Jonathan H Chung
Journal:  Am J Respir Crit Care Med       Date:  2019-03-15       Impact factor: 21.405

4.  High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival.

Authors:  Zulma X Yunt; Jonathan H Chung; Stephen Hobbs; Evans R Fernandez-Perez; Amy L Olson; Tristan J Huie; Rebecca C Keith; William J Janssen; Barbara L Goldstein; David A Lynch; Kevin K Brown; Jeffrey J Swigris; Joshua J Solomon
Journal:  Respir Med       Date:  2017-03-30       Impact factor: 3.415

5.  CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines.

Authors:  Jonathan H Chung; Justin M Oldham; Steven M Montner; Rekha Vij; Ayodeji Adegunsoye; Aliya N Husain; Imre Noth; David A Lynch; Mary E Strek
Journal:  AJR Am J Roentgenol       Date:  2018-03-16       Impact factor: 3.959

Review 6.  Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Fernando J Martinez
Journal:  N Engl J Med       Date:  2018-05-10       Impact factor: 91.245

7.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

8.  Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.

Authors:  Sabina A Guler; Kina Ellison; Mohmmed Algamdi; Harold R Collard; Christopher J Ryerson
Journal:  Ann Am Thorac Soc       Date:  2018-07

9.  Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease.

Authors:  Joseph Jacob; Jin Woo Song; Hee-Young Yoon; Gary Cross; Joseph Barnett; Wen Ling Woo; Fern Adams; Maria Kokosi; Anand Devaraj; Elisabetta Renzoni; Toby M Maher; Dong Soon Kim; Athol U Wells
Journal:  EBioMedicine       Date:  2018-01-31       Impact factor: 8.143

10.  Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Authors:  Kevin R Flaherty; Kevin K Brown; Athol U Wells; Emmanuelle Clerisme-Beaty; Harold R Collard; Vincent Cottin; Anand Devaraj; Yoshikazu Inoue; Florence Le Maulf; Luca Richeldi; Hendrik Schmidt; Simon Walsh; William Mezzanotte; Rozsa Schlenker-Herceg
Journal:  BMJ Open Respir Res       Date:  2017-09-17
View more
  16 in total

Review 1.  Update in Interstitial Lung Disease 2019.

Authors:  Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

2.  Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.

Authors:  Hideaki Yamakawa; Shintaro Sato; Emiri Tsumiyama; Tomotaka Nishizawa; Rie Kawabe; Tomohiro Oba; Teppei Kamikawa; Masanobu Horikoshi; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hidekazu Matsushima
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

3.  Will Adding Fibrotic Score to the GAP Score Help Predict Patient Survival?

Authors:  Jonathan H Chung
Journal:  Radiol Cardiothorac Imaging       Date:  2019-06-27

4.  Diagnostic test interpretation and referral delay in patients with interstitial lung disease.

Authors:  David Pritchard; Ayodeji Adegunsoye; Elyse Lafond; Janelle Vu Pugashetti; Ryan DiGeronimo; Noelle Boctor; Nandini Sarma; Isabella Pan; Mary Strek; Michael Kadoch; Jonathan H Chung; Justin M Oldham
Journal:  Respir Res       Date:  2019-11-12

Review 5.  Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).

Authors:  Paolo Spagnolo; Oliver Distler; Christopher J Ryerson; Argyris Tzouvelekis; Joyce S Lee; Francesco Bonella; Demosthenes Bouros; Anna-Maria Hoffmann-Vold; Bruno Crestani; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2020-10-09       Impact factor: 19.103

6. 

Authors:  David Lang; Florentine Moazedi-Fürst; Judith Sautner; Helmut Prosch; Sabin Handzhiev; Klaus Hackner; Ivan Tancevski; Holger Flick; Hubert Koller; Hans Peter Kiener; Christian Prior; Bernd Lamprecht
Journal:  Wien Klin Wochenschr       Date:  2021-05       Impact factor: 1.704

Review 7.  The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease.

Authors:  Ahmad Abu Qubo; K M Capaccione; Elana J Bernstein; Maria Padilla; Mary Salvatore
Journal:  Front Med (Lausanne)       Date:  2022-01-13

Review 8.  Cardio-Pulmonary Sequelae in Recovered COVID-19 Patients: Considerations for Primary Care.

Authors:  Zouina Sarfraz; Azza Sarfraz; Alanna Barrios; Radhika Garimella; Asimina Dominari; Manish Kc; Krunal Pandav; Juan C Pantoja; Varadha Retnakumar; Ivan Cherrez-Ojeda
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

9.  The natural history of progressive fibrosing interstitial lung diseases.

Authors:  Kevin K Brown; Fernando J Martinez; Simon L F Walsh; Victor J Thannickal; Antje Prasse; Rozsa Schlenker-Herceg; Rainer-Georg Goeldner; Emmanuelle Clerisme-Beaty; Kay Tetzlaff; Vincent Cottin; Athol U Wells
Journal:  Eur Respir J       Date:  2020-06-25       Impact factor: 16.671

10.  Clinical diagnosis of patients subjected to surgical lung biopsy with a probable usual interstitial pneumonia pattern on high-resolution computed tomography.

Authors:  Regina Celia Carlos Tibana; Maria Raquel Soares; Karin Mueller Storrer; Gustavo de Souza Portes Meirelles; Katia Hidemi Nishiyama; Israel Missrie; Ester Nei Aparecida Martins Coletta; Rimarcs Gomes Ferreira; Carlos Alberto de Castro Pereira
Journal:  BMC Pulm Med       Date:  2020-11-16       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.